-
Featured Authors
Patently BIOtech
Archive
- May 2013 (2)
- April 2013 (5)
- March 2013 (2)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- October 2012 (3)
- September 2012 (3)
- August 2012 (5)
- July 2012 (4)
- June 2012 (7)
- May 2012 (5)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
Preview: AUTM U.S. Licensing Survey: FY2011
We’ve seen compelling evidence recently about the positive impact of university licensing activity. As we learned from “The Economic Contributions of University/Nonprofit Inventions in the United States: 1996-2010,” a report released by BIO in June, university/nonprofit licensing supported as many as 3 million “person years of employment.” Now there is even more good news to share. AUTM publishes a report of academic licensing activity at the end of each year for the prior fiscal year. Read More >
BIO Voices Agree: Intellectual Property Delivers
Over the last year, the U.S. Chamber of Commerce’s Global IP Center (GIPC) has met with entrepreneurs from around the world to get their personal stories on what it takes to become a breakthrough innovator in the 21st century. While the products that these innovators create come in many shapes and sizes, all of those we’ve come into contact with—many of whom from the annual BIO International Convention—have displayed a resounding respect for and interest Read More >
Novartis at India Supreme Court: Evergreening Myths and Patent Reality
Novartis will go before India’s Supreme Court on September 11, 2012 challenging the refusal by the Indian Patent Office to grant a patent on its cancer drug Glivec. The Indian Patent Office rejected Novartis’ application under a provision in Indian law which is aimed at guarding against so called “patent evergreening.” BIO has written two posts deconstructing the myth of patent evergreening. 1. Patent “Ever-Greening”: Novartis Confronts Patent Myth in India 2. Patent Evergreening in Read More >
AMP v. Myriad: BIO Statement on Federal Circuit (Re)Decision
BIO released the following statement on the Federal Circuit’s decision in the AMP v. Myriad case on remand from the Supreme Court to reconsider in light of Mayo v. Prometheus. “Today’s decision by the U.S. Court of Appeals for the Federal Circuit confirms long-standing law under which valuable DNA preparations, bacterial enzymes, plant-derived antibiotics and other industrially and medically useful substances can be considered for patenting. Such patents have long provided critical incentives for expensive Read More >
Technology Transfer Impact? Senator Bayh Informs on IPWatchdog
IPWatchdog published an article by former Senator Birch Bayh highlighting a BIO commissioned study showing the economic impact of technology transfer on the U.S. economy. “A new study shows that this spinning of straw into gold is precisely what our academic research organizations have been quietly doing year after year. The just released report “The Economic Contribution of University/Nonprofit Inventions in the United States: 1996-2010” provides a much needed dose of good economic news when Read More >
